Overview

Trial of NovoSeven® in Haemophilia - Joint Bleeds

Status:
Completed

Trial end date:
2006-02-01

Target enrollment:

Participant gender:

Summary

This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds.

Phase:

Phase 4

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Anti-inhibitor coagulant complex